Buprenorphine/naloxone sublingual - Indivior
Alternative Names: Naloxone/buprenorphine; Sai Bo Song; SCH-000484; Suboxone; Suboxone film; SUBOXONE® TabletLatest Information Update: 07 Apr 2023
At a glance
- Originator Reckitt Benckiser Pharmaceuticals
- Developer Aquestive Therapeutics; Indivior; Reckitt Benckiser Pharmaceuticals
- Class Antidotes; Benzofurans; Cyclopropanes; Drug withdrawal therapies; Isoquinolines; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Opioid-related disorders
Most Recent Events
- 31 Dec 2022 Registered for Opioid-related disorders (In adolescents, In adults) in European Union prior to December (Sublingual)
- 31 Dec 2022 Registered for Opioid-related disorders in Australia prior to December (Sublingual)
- 24 Oct 2022 United States District Court of Pennsylvania dismisses litigation filed against Aquestive Therapeutics and Indivior by group of States’ Attorneys General in USA